Nomos' Peacock IMRT:
This article was originally published in Clinica
Executive Summary
North American Scientific's radiation oncology division, Nomos, has received approval in China to sell its flagship intensity modulated radiation therapy (IMRT) product for treating various cancers. The Peacock system consists of the firm's Corvus treatment planning software and its MIMiC multi-leaf collimator; sales of the equiptment could begin by the end of this month. Nomos is also in the process of registering in China its BAT family of products for image-guided radiation therapy, as well as Prospera I-125 brachytherapy seeds for treating prostate cancer.
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.